

5405 47

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number
WO 2004/063132 A1

(51) International Patent Classification⁷: C07C 49/173, 51/353, 59/90, 59/115 (74) Agent: CHOI, Kyu-Pal; Halla Classic Building 4F, 824-11, Yeoksam-dong, Kangnam-gu, Seoul 135-080 (KR).

(21) International Application Number:

PCT/KR2003/002470

(22) International Filing Date:

17 November 2003 (17.11.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2003-0002991 16 January 2003 (16.01.2003) KR

(71) Applicant (for all designated States except US): LG LIFE SCIENCES LTD. [KR/KR]; LG Twin Tower, East Tower, 20, Yido-dong, Yongsungpo-ku, 150-010 Seoul (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SHIN, Hyun-Ik [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, 305-380 Daejeon (KR). CHOI, Bo-Seung [KR/KR]; R & D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, 305-380 Daejeon (KR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/063132 A1

(54) Title: NOVEL PROCESS FOR PREPARING A 5-HYDROXY-3-OXO-HEXANOIC ACID DERIVATIVE


(57) Abstract: The present invention is related to a novel process for preparing an optically active 5-hydroxy-3-oxo-hexanoic acid derivative or its tautomer which is useful intermediate for preparing statins such as atorvastatin and rosuvastatin. Blaise reaction of (S)-4-halo-3-hydroxybutyronitrile with -haloacetate is utilized as a key reaction to provide the product with minimal formation of side products and in good yield.

NOVEL PROCESS FOR PREPARING A 5-HYDROXY-3-OXO-HEXANOIC ACID DERIVATIVE

TECHNICAL FIELD

5

The present invention is related to a novel process for preparing an optically active 5-hydroxy-3-oxo-hexanoic acid derivative of the following formula (1):



or its tautomer, in which

10 R represents hydrogen, saturated-C₁-C₄-alkyl, or unsaturated-C₂-C₄-alkyl, and X represents halogen such as Br, Cl, I, etc., which is a useful intermediate for preparing statins such as atorvastatin, rosuvastatin, etc. known as an agent for the treatment of hypercholesterolemia and hyperlipidemia.

15

BACKGROUND ART

In the existing process for preparing the above compound of formula (1), an optically active 3-hydroxyester compound was reacted with lithium enolate of *t*-butylacetate generated by the treatment of lithium diisopropylamide (LDA) or lithium hexamethyldisilazide (LHMDS) at low temperature (-78 °C) to provide compound of formula (1) (see: U. S. Patent No. 5,278,313). Recently, a similar reaction to the above was successfully carried out by the addition of Grignard reagent before Claisen condensation. This condition enabled the reaction performed at 5 °C (see: European Patent Laid-open Publication No. 1104750).

25

The above processes, however, used excess lithium hexamethyldisilazide or lithium diisopropylamide that has some problems to be used in the industrial production.

Moreover, the former route is complicated by the formation of significant amount of undesired side products even at very low temperature (see: *Tetrahedron Lett.*, 2002, 43, 2679-2682). The latter precedent results in pretty low yield comparing to the former process. The only advantage of the latter process is that the reaction can be executed at 5 5 °C.

DISCLOSURE OF THE INVENTION


The present inventors have conducted extensive researches to overcome the above problems of the existing processes. As a result, the inventors have developed a novel process for preparing the compound of formula (1) by Blaise reaction of (S)-4-halo-3-hydroxybutyronitrile and α -haloacetate using zinc metal activated in situ by an organic acid or its derivative. This novel route resulted in the formation of side products to a minimal quantity and all the reactions are executed at around ambient 15 temperature or above.

Therefore, the present invention provides an effective process for preparing the compound of formula (1), as defined above, or its tautomer using Blaise reaction which uses zinc metal activated in situ by an organic acid or its derivative.

20

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention is related to a process for preparing the compound of formula (1):




or its tautomer, in which

R represents hydrogen, saturated-C₁-C₄-alkyl, or unsaturated-C₂-C₄-alkyl, and

X represents halogen such as Br, Cl, I, etc., which comprises the following steps:


1) (*S*)-4-halo-3-hydroxybutyronitrile derivative of the following formula (2)



in which

5 X is as defined as above, and

P represents hydrogen or a hydroxy-protecting group, is reacted with an α -haloacetate compound of the following formula (3)




in which

10 R is as defined above, and

Y represents Br or I, in the presence of zinc metal activated by an organic acid or its derivative in an organic solvent and

2) the product of step 1) is hydrolyzed in the presence of aqueous acid solution.


15 The tautomer of the compound of formula (1) means the enol form compound of
the following formula (1a):



However, the compound of formula (1) is obtained as the main product of the process according to the present invention.

20

The key feature of the present invention is that the nitrile functionality of formula (2) is subjected to Blaise reaction of α -haloacetate of formula (3) using zinc metal activated by an organic acid or its derivative to introduce the β -ketoester group of formula (1). The reaction mechanism can be depicted as the following Reaction Scheme 1:

Reaction Scheme 1

In the process of the present invention, to a stirred suspension of zinc metal in 5 organic solvent is added catalytic amount of an organic acid or its derivative and the mixture is stirred under reflux to activate the zinc metal. To the mixture are added slowly the nitrile compound of formula (2) and the α -haloacetate compound of formula (3) in order to prepare the enamine intermediate of formula (4). After the completion of the 10 reaction, the whole mixture is hydrolyzed by aqueous acid solution to provide the desired compound of formula (1). The respective reaction conditions will be explained in more detail below.

The group P in formula (2) represents hydrogen or a hydroxy-protecting group. The hydroxy-protecting group includes SiRR^1R^2 wherein R is as defined above, and R^1 and R^2 each represent hydrogen, saturated- $\text{C}_1\text{-C}_6$ -alkyl, unsaturated- $\text{C}_2\text{-C}_6$ -alkyl, or 15 $\text{C}_6\text{-C}_{12}$ -aromatic group, and ethoxyethyl, and tetrahydropyranyl. The group SiRR^1R^2 preferably includes trimethylsilyl (TMS), triethylsilyl (TES), *t*-butyldimethylsilyl (TBDMS), and *t*-butyldiphenylsilyl (TBDPS). Trimethylsilyl is the most preferable as the hydroxy-protecting group in the aspect of purity and yield.

20

As reaction solvent, tetrahydrofuran, benzene, toluene and ether may be used. Among them, tetrahydrofuran is the most preferable in terms of purity and yield.

The α -haloacetate compound of formula (3) is added dropwise over 0.5 to 2.0 25 hours, and the purity and yield are the most satisfactory when the addition time is

between 1.0 and 1.5 hour. It is preferable to use the compound of formula (3) in an amount of 1.0 to 3.0 equiv with respect to the compound of formula (2). Particularly, it is good to use the compound of formula (3) wherein R is saturated-C₁-C₄-alkyl. Among the alkyl-haloacetate, isopropyl-haloacetate is better than methyl- or ethyl-haloacetate, and *t*-butyl-haloacetate is better than isopropyl-haloacetate in terms of yield.

5

The zinc metal is preferably used in an amount of 1.0 to 3.0 equiv with respect to the compound of formula (2). The zinc metal is usually stirred with solvent under reflux at a temperature ranging from 20 to 120 °C. It is preferable to use zinc dust or zinc powder.

10

As an organic acid or its derivative for activating the zinc metal, it is preferable to use R³CO₂H, R³SO₃H, R³CO₂TMS, R³SO₃TMS, or (R³SO₂)₂NH wherein R³ represents hydrogen, saturated-C₁-C₆-alkyl, unsaturated-C₂-C₆-alkyl, saturated-C₁-C₆-alkyl substituted by halogen, unsaturated-C₂-C₆-alkyl substituted by halogen, C₆-C₁₂-aromatic or C₆-C₁₂-aromatic substituted by halogen in 0.001 to 0.1 equiv with respect to the compound of formula (2).

15

Aqueous hydrochloric acid or sulfuric acid may be used in the hydrolysis reaction step and hydrochloric acid is more suitable. It is preferable to adjust the pH of the reaction solution to 3 to 4 in the aspect of purity and yield. The aqueous acid solution is added dropwise at a temperature ranging from 0 to 5 °C, and it is preferable to be stirred for hydrolysis at the same temperature.

20

The process according to the present invention provides advantages over the known precedents: 1) side products formation is minimized, 2) all the reactions are executed at around ambient temperature or above, 3) minimal use of reagents,

α -haloacetate compound and zinc, is accomplished by employing the organic acid mediated activation.


All these improvements should lead to efficient execution of the process, and
5 increased quality and yield of the product.

The present invention will be more specifically explained by the following example.

10

EXAMPLES

**Example 1: Preparation of (S)-6-chloro-5-hydroxy-3-oxo-hexanoic acid
t-butylester**



15 Zinc dust (690 mg), tetrahydrofuran (4.0 mL), and methanesulfonic acid (10 mg) were introduced into a reaction vessel and the mixture was stirred under reflux. To the mixture was added (S)-4-chloro-3-trimethylsilyloxybutyronitrile (1.00 g) and subsequently *t*-butylbromoacetate (2.04 g) over 1 hour. The mixture was stirred under reflux for 30 minutes, and cooled to 0 °C. Aqueous 3 N hydrochloric acid solution was
20 added dropwise until the acidity of the reaction solution became pH 4, and the reaction solution was stirred for 3 hours. After the completion of reaction, tetrahydrofuran was distilled off under reduced pressure, and the residue was extracted with ethyl acetate and purified by silica gel column chromatography (eluent: ethyl acetate/*n*-hexane=1/3, v/v) to give the title compound in a yield of 87% (1.07 g).

25 ^1H NMR (400MHz, CDCl_3) δ


Enol form (7%): 12.40 (bs, 1H), 5.01 (s, 1H), 4.19 (m, 1H), 3.61 (m, 2H), 2.88 (m, 2H), 2.54 (m, 1H), 2.49 (bs, 1H), 2.47 (m, 1H), 1.49 (s, 9H).

Keto Form (93%): 4.32 (m, 1H), 3.62 (m, 2H), 3.42 (s, 2H), 3.00 (bd, 1H), 2.88 (m, 2H), 1.48 (s, 9H).

Mass (ESI, m/z): 497 (2M+Na+2), 495 (2M+Na), 261 (M+Na+2), 259 (M+Na).

CLAIMS

1. A process for preparing a compound of formula (1)




5 or its tautomer, in which

R represents hydrogen, saturated-C₁-C₄-alkyl, or unsaturated-C₂-C₄-alkyl, and

X represents halogen, which comprises the following steps:

1) (S)-4-halo-3-hydroxybutyronitrile derivative of the following formula (2)



10 in which

X is as defined above, and

P represents hydrogen or a hydroxy-protecting group, is reacted with an α -haloacetate compound of the following formula (3)



15 in which

R is as defined above, and

Y represents Br or I, in the presence of zinc metal activated by an organic acid or its derivative in an organic solvent and

2) the product of step 1) is hydrolyzed in the presence of aqueous acid solution.

20

2. The process of claim 1 wherein P of the (S)-4-halo-3-hydroxybutyronitrile derivative of formula (2) represents hydrogen, or represents SiRR¹R² wherein R is as defined in claim 1, and R¹ and R² each represent hydrogen, saturated-C₁-C₆-alkyl, unsaturated-C₂-C₆-alkyl, or C₆-C₁₂-aromatic group, or represents ethoxyethyl or tetrahydropyranyl.

25

3. The process of claim 2 wherein P represents trimethylsilyl, triethylsilyl, *t*-butyldimethylsilyl, or *t*-butyldiphenylsilyl.
- 5 4. The process of claim 3 wherein P represents trimethylsilyl.
5. The process of claim 1 wherein the organic solvent is one or more selected from a group consisting of tetrahydrofuran, benzene, toluene, and ether.
- 10 6. The process of claim 5 wherein the organic solvent is tetrahydrofuran.
7. The process of claim 1 wherein R of the α -haloacetate compound of formula (3) represents saturated-C₁-C₄-alkyl.
- 15 8. The process of claim 7 wherein R represents *t*-butyl.
9. The process of claim 1 or 7 wherein the α -haloacetate compound of formula (3) is used in an amount of 1.0 to 3.0 equiv with respect to the compound of formula (2).
- 20 10. The process of claim 1 wherein the zinc metal is used in an amount of 1.0 to 3.0 equiv with respect to the compound of formula (2).
11. The process of claim 10 wherein the zinc metal is zinc dust or zinc powder.
- 25 12. The process of claim 1 wherein the organic acid or its derivative is selected from a group consisting of R³CO₂H, R³SO₃H, R³CO₂TMS, R³SO₃TMS, and (R³SO₂)₂NH wherein R³ represents hydrogen, saturated-C₁-C₆-alkyl, unsaturated-C₂-C₆-alkyl,

saturated-C₁-C₆-alkyl substituted by halogen, unsaturated-C₂-C₆-alkyl substituted by halogen, C₆-C₁₂-aromatic, or C₆-C₁₂-aromatic substituted by halogen.

13. The process of claim 12 wherein the organic acid or its derivative is used in an
5 amount of 0.001 to 0.1 equiv with respect to the compound of formula (2).

14. The process of claim 1 wherein the aqueous acid solution is aqueous hydrochloric
or sulfuric acid solution.

10 15. The process of claim 1 wherein the aqueous acid solution is added in an amount to
adjust the pH to 3 ~ 4.

16. The process of claim 15 wherein the aqueous acid solution is added dropwise at a
temperature ranging from 0 to 5 °C.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR2003/002470

A. CLASSIFICATION OF SUBJECT MATTER

IPC7 C07C 49/173, C07C 51/353, C07C 59/90, C07C 59/115

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7 C07C 49, C07C 51, C07C 59, C07D 319, C12P 7, C12R 1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean Patents and applications for inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN ONLINE (REG, CA, CASREACT)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5594153 A (E. R. Squibb & Sons, Inc.) 14 Jan 1997 See column 1, line 51- column 2, line 19; column 3, line 26 - column 4, line 20; example 4	1 - 16
A	SCHEFFLER et al.'Preparation and stereoselective hydrogenation of chiral (4-hydroxytetrafuranylidene)carboxylates: a new formal entry to functional anti- and syn-3,5-dihydroxy esters' Tetrahedron Letters (2002), 43(15), 2679-2682 See page 2679 (Scheme 1)	1 - 16
A	US 6340767 B (Kaneka Corporation) 22 Jan 2002 See abstract; column 2, line 19 - column 5, line 40	1 - 16
A	EP 1024139 A (Kaneka Corporation) 02 Oct 2000 See abstract; page 4, line 32 - page 5, line 13; page 9, line 14 - page 10, line 37; example 1 - 3	1 - 16
A	US 6399339 B (Forschungszentrum Julich GmbH) 04 Jun 2002 See column 5, line 38 - column 6, line 49; example 1	1 - 16

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

06 FEBRUARY 2004 (06.02.2004)

Date of mailing of the international search report

09 FEBRUARY 2004 (09.02.2004)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

SHIN, Gun Il

Telephone No. 82-42-481-5543



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2003/002470

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US5594153A	14.01.1997	NONE	
US6340767B	22.01.2002	W02000075099A CA2339357A AU2000051043A EP1104750A	14.12.2000 14.12.2000 28.12.2000 06.06.2001
EP1024139A	02.08.2000	CA2305564A1 CN1274356T HU0101122A2 N020001703A US6472544B1 W00008011A1	17.02.2000 22.11.2000 28.08.2001 03.04.2000 29.10.2002 17.02.2000
US6399339B	04.06.2002	DE19857302A1 EP1141373A1 W00036134A1	29.06.2000 10.10.2001 22.06.2000

End of line